Entrepreneur
Why less is more when it comes to skincare
How multi-use products could simplify skincare and tackle over-consumption
The skin is a direct mirror of how our body feels. Why not simplify our skincare routine and reduce waste, asks Pontine Paus, investor and entrepreneur.
Skincare products have the largest market share of all beauty industry segments and reports have shown that ‘skinimalism’ has various benefits.
Pontine Paus, entrepreneur and founder of Dr Lipp, says: “Indeed, the focus and knowledge we have today on how to live a healthy life has increased. It’s definitely good that we have this knowledgeable and know how to look after our skin, but I think it’s bad that we’re still using too many products that are not necessarily making a big a difference, but cause a lot of pollution in the world.”
Paus has launched her skincare brand 18 years ago when the multitude of brands and social media platforms we have today did not exist.
She started off with the original nipple balm that later became the signature product of the brand. “I used to have a lot of dry skin and a lot of eczema myself and I couldn’t find anything that worked until somebody said ‘why don’t you try some nipple balm’”, Paus remembers.
“I started doing a lot of research and there was just one ingredient, that’s been around since ancient Greek times and that is lanolin. So, I had this idea of taking the nipple balm out of the breastfeeding market and introducing it into the beauty market,” the founder explains.
Her main aim was to build a brand in which every product was multi-use with a maximum of 10 ingredients. “The average is 30 to 40 ingredients. So, we’ve reduced that massively. That’s probably the most effective and most important contribution that we can make when it comes to reducing our carbon footprint and helping with the biodiversity. I think if we can all consume more consciously, then that will have a big long-term impact.”
The nipple balm was just the start of her commitment to offer multi-use products in order to simplify people’s skincare routine and encourage a minimalistic approach.
“There are some great creams to help reduce wrinkles and pigmentation, for example, but the basic daily products, like hand cream, body lotion or any other cream, could all be one. In terms of washing, your makeup remover, your shampoo, your body wash, your shaving cream gel could all be one,” she says.
“I feel very strongly about the waste we’re creating and the big floating islands of plastic in the ocean,” she continues. “I’m horrified by how much rubbish every household produces every week, and where that goes and equally horrified about how polluted our food and water systems are. So, as a brand owner, I really looked at how to really make a difference.”
Statistics report that 120 billion units of packaging are produced every year by the global cosmetics industry, including lids, multi-layered boxes and cellophane that are most of the time non-recyclable.
“Everybody’s getting becoming more aware [of the environmental impacts], but we’ve got to think differently,” the founder insists. “Brands have got to offer products that reduce our waste rather than just recycling them. Nobody’s going to make it perfect, but we can improve on where we are at.”
With Latin words governing long ingredient lists, simple multi-use products can also give consumers a better understanding of what they are putting on their skin, the entrepreneur tells me. “I wanted something simple and 100 per cent natural,” she says. “A lot of brands do natural, but there’s no real big brands out there that do 100 per cent natural. But I think when it comes to these basic steps in our daily life, it’s much easier to make things simple.”
Paus’ hope is that more companies will come up with compostable packaging in the future.
“It would really make a huge difference, but sadly, the technology isn’t there yet. I hope at least we at Dr Lipp could make everything much simpler for both the people and the environment.”
Shop: The best-selling multi-use products from Dr Lipp
Dr Lipp Original Nipple Balm £12
Dr Lipp Superfood Tint Pack for Lips Cheeks and Eyelids £18
Juno Bio has secured US$3.8m to expand its diagnostics platform for vaginal health and reproductive care.
The funding round was led by Ada Ventures, with participation from Artesian, Entrepreneur First and Illumina Accelerator.
The women’s health startup said the seed funding will support the launch of its first CLIA-certified sequencing laboratory in Oakland, California, and a new clinical vaginal microbiome and STI test for healthcare providers.
CLIA certification refers to US laboratory standards for testing human samples used in diagnosis, prevention or treatment decisions.
Dr Leighton Turner, co-founder and chief scientific officer of Juno Bio, said: “The vaginal microbiome is still one of the least understood systems in the body at a clinical scale.
“With our lab, we’re starting to build a measurement standard that clinicians can actually use.
“We believe the level of detail from this kind of testing can meaningfully improve how vaginal healthcare is provided.”
The company is developing precision diagnostics for vaginal health, where patients can experience recurring symptoms, inconsistent diagnoses and treatments based on trial and error.
Juno Bio said bringing testing in-house gives it greater control over the process, from sample handling to results, while allowing it to refine its technology and build what it says is one of the largest datasets focused on the vaginal microbiome.
The vaginal microbiome is the community of bacteria and fungi that naturally live in the vagina. Changes in this balance can be linked to infections, symptoms and wider reproductive health issues.
Juno Bio’s newly launched clinical test examines the wider vaginal microbiome and screens for four common sexually transmitted infections, or STIs.
Rather than looking for a single cause, the test is intended to give clinicians a broader picture of what may be contributing to symptoms.
Juno Bio says this matters because multiple infections can occur at the same time and microbiome changes may be linked to fertility, menopause or recurrent infections.
Dr Anna Powell of Johns Hopkins said: “Vaginal microbiome testing has the potential to significantly reshape how we understand and manage vaginal health, particularly for patients with recurrent or unexplained symptoms.
“While the field is still evolving, advances in sequencing and data interpretation are moving us closer to a future where more personalised, microbiome-informed care can complement existing diagnostic approaches.”
Check Warner, co-founding partner at Ada Ventures, added: “Juno Bio is setting a new standard for how vaginal health is understood and managed.
“What they’ve built at this stage, with this level of capital efficiency, is exceptional.
“We’re proud to support the team as they scale their clinical infrastructure and continue leading innovation in this critically underserved category.”
Women’s health companies raised a record $1.55 billion in disclosed equity in 2025, up 41 per cent year on year, according to W Group’s first Global Women’s Health Investment Report, The Road to the Era of Scale.
The report tracks over 500 funding stories and 164 equity rounds across 15 categories and 30+ countries.
Eighty-five companies raised equity in 2025, the highest single-year count on record. But according to the report, the headline figure isn’t the most significant one.
The bigger shift is in where that capital went and how concentrated it was at the top compared to the year before.
The report also points to a brand new investment category that didn’t exist twelve months ago.
SheMed closed a $50 million Series A this year to build a women-specific GLP-1 and metabolic health platform, the first dedicated raise of its kind.
Alongside the momentum, the report identifies one structural risk that could determine whether 2025’s growth holds: a bottleneck at Series A that’s leaving a number of promising seed-stage companies stuck.
Molly Taylor, head of content at W Group, said: “2025 was the biggest year women’s health has ever had, and the most important finding isn’t the headline number.
“It’s that the money has stopped pooling at the top.
“Capital is reaching more companies, more categories and more countries than ever before. The Era of Scale is real. It’s just not finished, and the Series A gap is where it could stall.
“Closing that gap is the highest-leverage move this ecosystem can make in 2026.”
Read the full report: https://wplatform.co/forms/womens-health-equity-funding-trends-report-2026?utm_source=advocacy&utm_medium=ext_email&utm_campaign=2026-q3-health-report-femtech-world
Onto Health has acquired Levy Health, a fertility software company providing precision diagnostics and patient intake for reproductive medicine.
The acquisition, fuelled by Onto Health’s US$20m Series A fundraise in April, supports its plan to build scalable, tech-enabled infrastructure for reproductive medicine.
Onto founder Roohi Jeelani, MD, called it the first of several moves in the company’s expansion strategy in a LinkedIn post, adding that there was “more coming soon”.
She said: “This isn’t just an acquisition, it’s proof of how we’re building Onto: physician-led, tech-enabled, and built to scale without losing the personal touch fertility patients deserve.”
Headquartered in Chicago, Onto Health combines evidence-based fertility care with artificial intelligence-driven diagnostics, clinical automation and longevity science.
AI-driven diagnostics use software to analyse patient information and support clinical decision-making, rather than replace clinicians.
Levy Health, founded in Berlin with US offices in San Francisco, helps medical providers identify endocrine disorders more quickly and helps clinics streamline fertility workups.
Endocrine disorders affect the body’s hormone system, which can influence ovulation, menstrual cycles and fertility.
Co-founder Caroline Mitterdorfer said joining Onto would expand Levy Health’s fertility care tools to more clinics and patients, helping physicians focus on patient care.
Onto opened its first clinic in Chicago in February, with plans for three more in the greater Chicago area.
The company said in April that it would use its new funding, led by Artis and Humania, to support additional operations in the US and expand into the Gulf Cooperation Council.
The Gulf Cooperation Council includes six Arab states bordering the Persian Gulf.
Diagnosis2 weeks agoTwo “gamechanger” tests set to speed up endometriosis diagnosis on the NHS
Insight2 weeks agoWomen with PMOS should have annual NHS checks, new guidance says
News4 days agoNew menopause drug approved for use by NHS in Scotland
Cancer2 weeks agoThousands of women could avoid painful cancer exam with new AI blood test
Entrepreneur1 week agoApplications open for the third W Accelerate with Merck KGaA and M Ventures
Fertility2 weeks agoOlder women face lower chance of fertility treatment working, even with donor eggs, study finds
Opinion2 weeks agoWe built Ema like a nurse: Here’s why that matters
News2 weeks agoExperts call for regulation of toxic period product chemicals
Pingback: Selva Ventures raises US$34m to invest in health and wellness businesses - FemTech World
Pingback: Skincare telehealth start-up raises US$52m ahead of expansion - FemTech World